As investors look ahead to data shortly from Veru Inc. with enobosarm, the weight-loss space remains hot, with Novo Nordisk A/S reporting favorable top-line results from a phase Ib/IIa trial ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk A/S has a 12-month low of $81.50 and a 12-month high of $148.15. The company has a market cap of $384.27 billion, a P/E ratio of 27.71, a PEG ratio of 1.37 and a beta of 0.45.

DHAKA, BANGLADESH – Media OutReach Newswire – 10 January 2025 – The Best Places to Work certification program has recognized Foodpanda and Novo Nordisk as the top two best places to work in ...

Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop ...

Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and ...

Shares of Sana Biotechnology Inc. (NASDAQ: SANA) were trading at $4.97, up $3.32, or 201%, on first results from an investigator-sponsored, first-in-human study transplanting UP-421, an allogeneic ...

On Tuesday, his company, Variant Bio, based in Seattle, announced a $50 million collaboration with drugmaker Novo Nordisk to develop drugs for metabolic disorders, including diabetes and obesity ...

Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic disease targets.

SEATTLE, WA, USA I January 7, 2025 I Variant Bio, a genomics-driven drug discovery company, today announced a multi-year research collaboration with Novo Nordisk to discover novel targets for the ...